Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24872010 | 0.82 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL20939381 | 0.77 | NLRP3 (0.42) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20400046 | 0.76 | NLRP3 (0.39) | NLRP3ALOX5ALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL18209909 | 0.75 | NLRP3 (0.38) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL22021007 | 0.73 | NLRP3 (0.40) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20828220 | 0.73 | ALOX5 (0.41) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL18215107 | 0.72 | ALOX5 (0.40) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL20400203 | 0.71 | NLRP3 (0.38) | NLRP3 | |
| SCHEMBL20400392 | 0.71 | NLRP3 (0.48) | NLRP3ALOX5ALOX5APFEN1 | |
| SCHEMBL22193802 | 0.70 | NLRP3 (0.36) | NLRP3ALOX5ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ALOX5 832/4885ALOX5AP 285/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ALOX5 796/4885ALOX5AP 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.